On one hand, low dose IL2 has been proposed as treatment option for certain conditions like graft-versus-host disease [42], systemic lupus erythematosus [43] and hepatitis C virus-induced vasculitis [44]. This evidence concerns the gene IL2 and graft versus host disease.